Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33,694Revenue $M6,298Net Margin (%)21.9Altman Z-Score3.6
Enterprise Value $M35,873EPS $16.2Operating Margin %22.8Piotroski F-Score5
P/E(ttm)10.5Beneish M-Score-3.1Pre-tax Margin (%)22.4Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio0.5Cash flow > EarningsY
Price/Sales7.15-y EBITDA Growth Rate %27.7Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow9.7y-y EBITDA Growth Rate %6.3ROA % (ttm)6.7Higher Current Ratio y-yN
Dividend Yield %0.4PEG0.4ROE % (ttm)12.2Less Shares Outstanding y-yN
Payout Ratio %5.0Shares Outstanding M200ROIC % (ttm)11.4Gross Margin Increase y-yY

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGKen Fisher 2015-12-31 Add$188.55 - $231.08
($207.88)
$ 157.32-24%Add 9.30%33,954
SHPGLeon Cooperman 2015-09-30 Reduce-1.74%$197.88 - $268.08
($237.86)
$ 157.32-34%Reduce -90.86%45,367
SHPGJohn Paulson 2015-09-30 Reduce-0.33%$197.88 - $268.08
($237.86)
$ 157.32-34%Reduce -4.09%6,805,200
SHPGKen Fisher 2015-09-30 Add$197.88 - $268.08
($237.86)
$ 157.32-34%Add 54.08%31,064
SHPGJohn Paulson 2015-06-30 Reduce-1.55%$226.9 - $260.15
($247.87)
$ 157.32-37%Reduce -14.81%7,095,100
SHPGFirst Eagle Investment 2015-06-30 Reduce-0.17%$226.9 - $260.15
($247.87)
$ 157.32-37%Reduce -98.36%4,830
SHPGLeon Cooperman 2015-06-30 Reduce-0.02%$226.9 - $260.15
($247.87)
$ 157.32-37%Reduce -0.80%496,192
SHPGKen Fisher 2015-06-30 Add$226.9 - $260.15
($247.87)
$ 157.32-37%Add 36.31%20,161
SHPGFirst Eagle Investment 2015-03-31 Add0.12%$205.66 - $253.64
($229.81)
$ 157.32-32%Add 254.93%294,539
SHPGLeon Cooperman 2015-03-31 Add0.1%$205.66 - $253.64
($229.81)
$ 157.32-32%Add 5.70%500,192
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 157.32-32%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 157.32-32%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 157.32-26%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 157.32-26%Reduce -7.93%8,328,304
SHPGDavid Tepper 2014-12-31 Sold Out -0.71%$170.49 - $262.71
($211.58)
$ 157.32-26%Sold Out0
SHPGFirst Eagle Investment 2014-12-31 Add0.04%$170.49 - $262.71
($211.58)
$ 157.32-26%Add 453.24%82,986
SHPGMario Gabelli 2014-12-31 Reduce-0.03%$170.49 - $262.71
($211.58)
$ 157.32-26%Reduce -57.13%16,225
SHPGKen Fisher 2014-12-31 Add0.01%$170.49 - $262.71
($211.58)
$ 157.32-26%Add 416.24%14,594
SHPGJohn Paulson 2014-09-30 Add6.09%$231.98 - $262.64
($248.14)
$ 157.32-37%Add 168.70%9,046,000
SHPGDavid Tepper 2014-09-30 Buy 0.71%$231.98 - $262.64
($248.14)
$ 157.32-37%New holding185,944
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about SHPG:

    News about SHPG:

    Articles On GuruFocus.com
    Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
    John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
    Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
    Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
    Manning & Napier Invests in Stake in Baidu Jul 08 2015 
    Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
    Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
    Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
    8 Top Healthcare Stocks to Watch May 13 2015 
    John Paulson's Stocks Trading at Low P/E May 04 2015 

    More From Other Websites
    Shire's NDA Resubmission for Lifitegrast Accepted by FDA Feb 05 2016
    Momentum, Strategy within Today's Market - Analyst Notes on AmerisourceBergen, Xcel Energy, Shire... Feb 05 2016
    U.S. FDA Acknowledges Receipt of Resubmission of Shire's New Drug Application for Lifitegrast for... Feb 04 2016
    Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Feb 04 2016
    Will AmerisourceBergen's (ABC) Q1 Earnings Disappoint? Feb 03 2016
    SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 03 2016
    Headline Risk Is Poison for Pharma and Biotech Feb 03 2016
    SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 01 2016
    Total Voting Rights Feb 01 2016
    AbbVie cuts costs, turns profit that meets 4Q expectations Jan 29 2016
    SHIRE PLC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Jan 28 2016
    Pharma firm gets FDA approval for ADHD drug, more jobs likely Jan 28 2016
    Shire PLC assigned investment grade ... Jan 28 2016
    Shire plc Assigned Investment Grade Credit Ratings by Moody's and S&P Jan 28 2016
    Shire to announce Full Year 2015 ... Jan 28 2016
    Shire plc -- Moody's assigns Baa3 issuer rating to Shire plc; stable outlook Jan 28 2016
    The Baxalta–Shire merger: Basics of Shire Pharmaceuticals Jan 26 2016
    Shire stays mum on Burlington facilities, employees in wake of Dyax acquisition Jan 25 2016
    Shire Resubmits New Drug Application ... Jan 25 2016
    Shire Resubmits New Drug Application for Lifitegrast to U.S. FDA Jan 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK